Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cornerstone Pharmaceuticals, focused on therapies exploiting distinctive cancer cell metabolism, has entered into a collaboration agreement with the US National Cancer Institute (NCI) to evaluate Cornerstone's selective cancer cell targeting nanotechnology.
Subscribe to our email newsletter
The collaboration calls for Cornerstone to apply its Emulsiphan cancer selective delivery nanotechnology platform to a class of agents developed at the NCI’s Center for Cancer Research Nanobiology Program. Cornerstone and NCI will evaluate the potential of the combined technologies in reducing tumors.
Cornerstone has been able to formulate multiple types of anti-cancer compounds in Emulsiphan, its lipid oil nanoemulsion. Emulsiphan is designed to maximize drug concentration into tumor cells thereby enhancing the anti-cancer compound’s selectivity and specificity, leading to a potentially safer and more effective cancer treatment. The NCI and Cornerstone have agreed to collaborate to evaluate the combination of these agents with Emulsiphan.
Cornerstone’s Emulsiphan drug delivery technology aims to overcome the challenges so that increasing the required effective dose doesn’t deliver treatment at the expense of risking a patient’s safety.
Robert Shorr, chief executive officer of Cornerstone Pharmaceuticals, said: “This is an important step forward towards achieving the dream of safe and effective cancer therapy for the most difficult to treat cancer types. We are excited to work with the NCI and look forward to progressing from studies in cell tumor models to actual human clinical studies.”